Marconcini, Riccardo

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

Cortellini, A., Bersanelli, M., Buti, S., Cannita, K., Santini, D., Perrone, F., Giusti, R., Tiseo, M., Michiara, M., Di Marino, P., et al. (2019) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersCancer Risks and Factors

Cited by 413

Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma

Diem, S., Kasenda, B., Spain, L., Martin-Liberal, J., Marconcini, R., Gore, M., & Larkin, J. (2016) · British Journal of Cancer

Cancer Immunotherapy and BiomarkersCutaneous Melanoma Detection and Management

Cited by 308

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

Cortellini, A., Tucci, M., Adamo, V., Stucci, L. S., Russo, A., Tanda, E. T., Spagnolo, F., Rastelli, F., Bisonni, R., Santini, D., et al. (2020) · Journal for ImmunoTherapy of Cancer

Cancer Immunotherapy and BiomarkersFerroptosis and cancer prognosis

Cited by 275